Corporate News Blog Akari Therapeutics Announces Enrolment of A - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Corporate News Blog Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)

LONDON, UK / ACCESSWIRE / October 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Akari Therapeutics, PLC (NASDAQ: AKTX) (“Akari”), following which, we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=AKTX. The Company announced on October 11, 2017, the enrolment of three additional patients in the ongoing Phase-II COBALT clinical trial of Coversin™ in patients with paroxysmal nocturnal hemoglobinuria (PNH). For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on AKTX. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=AKTX

Progress of COBALT Phase-II Clinical Trial

Out of the eight patients enrolled in COBALT, the Phase-II 90-day, open label single arm clinical trial, four have completed the trial and have all moved into Akari’s long-term safety study, CONSERVE. The data was presented at the 22nd Congress of the European Hematology Association (EHA) in June 2017. One of the initial five patients enrolled was withdrawn from the study on day 43.

Pursuant to an amended protocol based on a revised dosing regimen, three new patients were enrolled, who have now completed approximately 8, 3, and 2 weeks, respectively. The first of the three patients had an LDH (lactate dehydrogenase) value of 1.5 times the ULN at day 28, meeting the primary endpoint of serum LDH reduction to ≤1.8 times the ULN. The other two patients have not yet reached the primary endpoint measurement date. No drug-related serious adverse events were reported.

Akari Announces Regulatory Progress Following FDA Meeting

Following advice of United States Food and Drug Administration (FDA), the Company plans to advance Coversin™ towards Phase-III clinical trials, beginning with CAPSTONE in Q1 2018, a Phase-III clinical trial of Coversin™ in naïve PNH patients.

Akari Demonstrated Positive Response with Coversin™ in Phase-2 PNH Trial

On April 24, 2017, Akari presented data from an interim analysis of its Phase-2 trial of Coversin™ in PNH, as well as preclinical data for additional indications and other opportunities, at Research and Development Day. The Company demonstrated positive response from the trial.

About Coversin™

Coversin™ is Akari’s lead product candidate. It is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick. Coversin™ is a second-generation and potentially best-in-class complement inhibitor, acts on complement component-C5, preventing release of C5a and formation of C5b–9.

Akari’s initial clinical targets for Coversin™ are PNH and atypical Hemolytic Uremic Syndrome. To date, the Company has demonstrated full complement inhibition and marked lactate dehydrogenase reduction in a PNH patient with eculizumab resistance.

About Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH is a rare, chronic, debilitating disorder that most frequently presents in early adulthood and usually continues throughout the life of the patient. PNH results in the death of approximately 50% of affected individuals due to thrombotic complications, and until recently, had no specific therapy.

About Akari Therapeutics, Plc (NASDAQ: AKTX)

Founded in 2005, Akari is a biopharmaceutical Company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system, and the bioamine system for the treatment of rare and orphan diseases, in particular, those where the complement system or leukotrienes, or both complement and leukotrienes together play a primary role in disease progression. The Company is based in New York City, New York.

Last Close Stock Review

On Thursday, October 12, 2017, the stock closed the trading session at $6.96, dropping 5.95% from its previous closing price of $7.40. A total volume of 310.94 thousand shares have exchanged hands. Akari Therapeutics’ stock price skyrocketed 7.24% in the last one month and 52.97% in the past three months. The stock currently has a market cap of $83.31 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 477725

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

Powered by Frankly